These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 29054987)
1. Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Krasniqi A; D'Huyvetter M; Xavier C; Van der Jeught K; Muyldermans S; Van Der Heyden J; Lahoutte T; Tavernier J; Devoogdt N Mol Cancer Ther; 2017 Dec; 16(12):2828-2839. PubMed ID: 29054987 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20. Krasniqi A; Bialkowska M; Xavier C; Van der Jeught K; Muyldermans S; Devoogdt N; D'Huyvetter M N Biotechnol; 2018 Oct; 45():69-79. PubMed ID: 29574274 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma. Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665 [TBL] [Abstract][Full Text] [Related]
4. Preclinical study of Durand-Panteix S; Monteil J; Sage M; Garot A; Clavel M; Saidi A; Torgue J; Cogne M; Quelven I Br J Cancer; 2021 Dec; 125(12):1657-1665. PubMed ID: 34671126 [TBL] [Abstract][Full Text] [Related]
5. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366 [TBL] [Abstract][Full Text] [Related]
6. Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using Havlena GT; Kapadia NS; Huang P; Song H; Engles J; Brechbiel M; Sgouros G; Wahl RL J Nucl Med; 2023 Jan; 64(1):109-116. PubMed ID: 35981897 [TBL] [Abstract][Full Text] [Related]
7. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma. Yadav MP; Singla S; Thakral P; Ballal S; Bal C Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315 [TBL] [Abstract][Full Text] [Related]
19. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889 [TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]